Shaanxi encourages innovation in pharmaceutical and medical devices: imitating new drugs and giving priority to health insurance

category:Society click:617
 Shaanxi encourages innovation in pharmaceutical and medical devices: imitating new drugs and giving priority to health insurance


Shaanxi Food and Drug Administration said that the program encourages enterprises to develop and imitate medicines that are clinically necessary, effective and in short supply, and to develop and imitate medicines needed for the prevention and treatment of major infectious diseases and rare diseases. Provincial Food and Drug Administration will timely grasp the list information of drugs whose patent rights expire, terminate, invalid and have not yet been applied for copying, and publish it to the public in time to guide pharmaceutical manufacturers to develop generic drug research and production. At the same time, we should support the clinical application of new drugs, give strong support to the major innovative drugs in our province and the varieties settled in Shaanxi, coordinate the relevant departments at the provincial level, and timely bring the newly approved drugs on the market or through consistency evaluation into the payment scope of medical insurance in our province and the centralized purchasing scope of drugs in medical and health institutions. Encourage medical institutions to give priority to the purchase and use of new drugs with definite efficacy and reasonable prices. For applications for registration of innovative medical devices with core technology patents and significant clinical value, the food and drug regulatory authorities will give priority to acceptance and processing. The implementation plan also put forward a number of incentive policies. To reward new products of pharmaceutical and medical devices, the maximum amount of subsidies for first class new drugs is not more than 20 million yuan; for second class new drugs, the maximum amount of subsidies is not more than 10 million yuan; and for third class new drugs, the maximum amount of subsidies is not more than 5 million yuan. For the enterprises that passed the conformity evaluation of generic drugs, the provincial finance awarded 3 million yuan to each drug manufacturer. The source of this article is: Li Lin, the editor in charge of Hua Shang net and China business newspaper: Huang Jia _NNB6466

The implementation plan also put forward a number of incentive policies. To reward new products of pharmaceutical and medical devices, the maximum amount of subsidies for first class new drugs is not more than 20 million yuan; for second class new drugs, the maximum amount of subsidies is not more than 10 million yuan; and for third class new drugs, the maximum amount of subsidies is not more than 5 million yuan. For the enterprises that passed the conformity evaluation of generic drugs, the provincial finance awarded 3 million yuan to each drug manufacturer.